Penny, C. L., Quow, K., Rundle, C. W., Al-Rohil, R. N., Cardones, A. R., Kheterpal, M. K., & Fresco, A. I. (2022). Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol, 187(2), 275–276. https://doi.org/10.1111/bjd.21239

Penny, Caitlin L., Krystina Quow, Chandler W. Rundle, Rami N. Al-Rohil, Adela R. Cardones, Meenal K. Kheterpal, and Amber I. Fresco. “Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.” Br J Dermatol 187, no. 2 (August 2022): 275–76. https://doi.org/10.1111/bjd.21239.

Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, et al. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol. 2022 Aug;187(2):275–6.

Penny, Caitlin L., et al. “Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.” Br J Dermatol, vol. 187, no. 2, Aug. 2022, pp. 275–76. Pubmed, doi:10.1111/bjd.21239.

Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, Fresco AI. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol. 2022 Aug;187(2):275–276.